AU3360800A - Epoxide hydrolase complexes and methods therewith - Google Patents

Epoxide hydrolase complexes and methods therewith

Info

Publication number
AU3360800A
AU3360800A AU33608/00A AU3360800A AU3360800A AU 3360800 A AU3360800 A AU 3360800A AU 33608/00 A AU33608/00 A AU 33608/00A AU 3360800 A AU3360800 A AU 3360800A AU 3360800 A AU3360800 A AU 3360800A
Authority
AU
Australia
Prior art keywords
sulfur
oxygen
hydrogen
nitrogen
epoxide hydrolase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU33608/00A
Other languages
English (en)
Inventor
Marvin H. Goodrow
Bruce D Hammock
Christophe H. Morisseau
James Sanborn
Tonya Severson
Jiang Zheng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
University of California Berkeley
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, University of California Berkeley filed Critical University of California
Publication of AU3360800A publication Critical patent/AU3360800A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
AU33608/00A 1999-02-18 2000-02-10 Epoxide hydrolase complexes and methods therewith Abandoned AU3360800A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/252,148 US6150415A (en) 1996-08-13 1999-02-18 Epoxide hydrolase complexes and methods therewith
US09252148 1999-02-18
PCT/US2000/003495 WO2000048593A1 (en) 1999-02-18 2000-02-10 Epoxide hydrolase complexes and methods therewith

Publications (1)

Publication Number Publication Date
AU3360800A true AU3360800A (en) 2000-09-04

Family

ID=22954799

Family Applications (1)

Application Number Title Priority Date Filing Date
AU33608/00A Abandoned AU3360800A (en) 1999-02-18 2000-02-10 Epoxide hydrolase complexes and methods therewith

Country Status (10)

Country Link
US (1) US6150415A (enExample)
EP (2) EP1154764B1 (enExample)
JP (1) JP2002540767A (enExample)
AT (1) ATE375153T1 (enExample)
AU (1) AU3360800A (enExample)
CA (1) CA2362331C (enExample)
DE (1) DE60036690T2 (enExample)
DK (1) DK1154764T3 (enExample)
ES (1) ES2291196T3 (enExample)
WO (1) WO2000048593A1 (enExample)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150415A (en) * 1996-08-13 2000-11-21 The Regents Of The University Of California Epoxide hydrolase complexes and methods therewith
US8815951B2 (en) * 1996-08-13 2014-08-26 The Regents Of The University Of California Inhibitors of epoxide hydrolases for the treatment of inflammation
US7517880B2 (en) 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
EP1140840B1 (en) * 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ATE538794T1 (de) 1999-01-13 2012-01-15 Bayer Healthcare Llc Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
US7928239B2 (en) 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
RU2319693C9 (ru) 1999-01-13 2008-08-20 Байер Копэрейшн Производные мочевины (варианты), фармацевтическая композиция (варианты) и способ лечения заболевания, связанного с ростом раковых клеток (варианты)
US6831099B1 (en) * 1999-05-12 2004-12-14 Yale University Enzyme inhibition
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
US6562563B1 (en) * 1999-11-03 2003-05-13 Mitokor Compositions and mehtods for determining interactions of mitochondrial components, and for identifying agents that alter such interactions
US7235576B1 (en) 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
WO2002082082A2 (en) * 2001-04-09 2002-10-17 Boehringer Ingelheim Pharmaceuticals, Inc. Fluorescence polarization assay
US7371763B2 (en) 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
US6756210B2 (en) * 2001-05-29 2004-06-29 The Regents Of The University Of California Linoleic acid diol and glucuronide conjugate levels as diagnostic markers of disorders of abnormal regulation of cytochrome P450 metabolism of unsaturated fatty acids
US6979733B2 (en) * 2001-08-03 2005-12-27 Diversa Corporation Epoxide hydrolases, nucleic acids encoding them and methods of making and using them
US6943001B2 (en) * 2001-08-03 2005-09-13 Diversa Corporation Epoxide hydrolases, nucleic acids encoding them and methods for making and using them
US20030139469A1 (en) * 2002-01-23 2003-07-24 The Regents Of The University Of California Use of inhibitors of soluble epoxide hydrolase to inhibit vascular smooth muscle cell proliferation
SI1478358T1 (sl) 2002-02-11 2013-09-30 Bayer Healthcare Llc Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi
SI1580188T1 (sl) 2002-02-11 2012-02-29 Bayer Healthcare Llc Aril sečnine kot kinazni inhibitorji
US20030216396A1 (en) 2002-02-11 2003-11-20 Bayer Corporation Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors
GB0214342D0 (en) * 2002-06-21 2002-07-31 Givaudan Sa Insect repellents
JP4515911B2 (ja) 2002-10-07 2010-08-04 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア アナンダミド加水分解の遮断による不安の調節
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
US20050164951A1 (en) * 2003-04-03 2005-07-28 The Regents Of The University Of California Inhibitors for the soluble epoxide hydrolase
CA2520763A1 (en) * 2003-04-03 2004-10-21 The Regents Of The University Of California Improved inhibitors for the soluble epoxide hydrolase
EP1626714B1 (en) 2003-05-20 2007-07-04 Bayer Pharmaceuticals Corporation Diaryl ureas for diseases mediated by pdgfr
EP1663978B1 (en) 2003-07-23 2007-11-28 Bayer Pharmaceuticals Corporation Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
CA2559665A1 (en) 2004-03-16 2005-09-29 The Regents Of The University Of California Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
US7662910B2 (en) 2004-10-20 2010-02-16 The Regents Of The University Of California Inhibitors for the soluble epoxide hydrolase
JP2008540424A (ja) * 2005-05-06 2008-11-20 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ｓＥＨインヒビターとしてのアシルヒドラゾンの使用方法
EP1885697A2 (en) * 2005-05-06 2008-02-13 Boehringer Ingelheim International Gmbh Soluble epoxide hydrolase inhibitors and methods of using same
US9119837B2 (en) * 2005-08-19 2015-09-01 The Regents Of The University Of California Use of sEH inhibitors as analgesics
CA2622754A1 (en) * 2005-10-07 2007-04-19 Boehringer Ingelheim International Gmbh N-substituted pyridinone or pyrimidinone compounds useful as soluble epoxide hydrolase inhibitors
KR101434522B1 (ko) 2005-11-09 2014-08-26 오닉스 세라퓨틱스, 인크. 효소 저해를 위한 화합물
JP2009523134A (ja) * 2006-01-13 2009-06-18 マクギル ユニバーシティー 抗うつ作用ならびに睡眠誘発性を有する新規なメラトニンリガンド
WO2007106705A1 (en) * 2006-03-10 2007-09-20 Boehringer Ingelheim International Gmbh Soluble epoxide hydrolase inhibitors and methods of using same
AR059826A1 (es) * 2006-03-13 2008-04-30 Univ California Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble
RU2450016C2 (ru) 2006-06-19 2012-05-10 Протеоликс, Инк. Пептидные эпоксикетоны для ингибирования протеасомы
WO2008073130A1 (en) * 2006-12-15 2008-06-19 Regents Of The University Of California Use of cis-epoxyeicosatrienoic acids and inhibitors of soluble epoxide hydrolase to treat conditions mediated by pbr, cb2, and nk2 receptors
EP2091542A1 (en) * 2006-12-18 2009-08-26 F. Hoffmann-Roche AG Novel use of inhibitors of soluble epoxide hydrolase
EP2178534A4 (en) * 2007-07-17 2011-03-30 Merck Sharp & Dohme SOLUBLE EPOXYHYDROLASE HEMMER, COMPOSITIONS WITH SUCH COMPOUNDS AND TREATMENT METHODS THEREWITH
WO2009020960A1 (en) 2007-08-06 2009-02-12 The Regents Of The University Of California Preparation of novel 1,3-substituted ureas as inhibitors of soluble epoxide hydrolase
SI2207791T2 (sl) * 2007-10-04 2019-09-30 Onyx Therapeutics, Inc. Kristalinični peptidepoksiketonski proteazni inhibitorji in sinteza aminokislinskih ketoepoksidov
EP2259680A4 (en) * 2008-03-04 2012-01-25 Merck Sharp & Dohme SOLUBLE EPOXYHYDROLASE INHIBITORS, COMPOSITIONS COMPRISING SUCH COMPOUNDS AND TREATMENT METHODS THEREWITH
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2796134B1 (en) 2008-10-21 2016-12-07 Onyx Therapeutics, Inc. Combination of the peptide epoxyketone proteasome inhibitor carfilzomib with melphalan for use in the treatment of multiple myeloma
WO2010096722A1 (en) 2009-02-20 2010-08-26 Takeda Pharmaceutical Company Limited 3-oxo-2, 3-dihydro- [1,2, 4] triazolo [4, 3-a]pyridines as soluble epoxide hydrolase (seh) inhibitors
AR075899A1 (es) 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
EP2498793B1 (en) 2009-11-13 2019-07-10 Onyx Therapeutics, Inc. Oprozomib for use in metastasis suppression
EP2528604B1 (en) 2010-01-29 2017-11-22 The Regents of the University of California Acyl piperidine inhibitors of soluble epoxide hydrolase
AU2011223795B2 (en) 2010-03-01 2015-11-05 Onyx Therapeutics, Inc. Compounds for immunoproteasome inhibition
KR20130094185A (ko) 2010-04-07 2013-08-23 오닉스 세라퓨틱스, 인크. 결정성 펩티드 에폭시케톤 면역프로테아좀 저해제
EP2389922A1 (en) 2010-05-25 2011-11-30 Symrise AG Cyclohexyl carbamate compounds as anti-ageing actives
EP2675274B1 (en) 2011-02-14 2017-05-03 The Regents of The University of California SORAFENIB DERIVATIVES AS sEH INHIBITORS
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
WO2013116690A1 (en) 2012-02-01 2013-08-08 The Regents Of The University Of California Acyl piperidine inhibitors of soluble epoxide hydrolase
US10383835B2 (en) 2012-03-14 2019-08-20 The Regents Of The University Of California Treatment of inflammatory disorders in non-human mammals
US20140105921A1 (en) 2012-07-09 2014-04-17 Onyx Therapeutics, Inc. Prodrugs of Peptide Epoxy Ketone Protease Inhibitors
WO2016133788A1 (en) 2015-02-20 2016-08-25 The Regents Of The University Of California Methods of inhibiting pain
WO2017202957A1 (en) 2016-05-25 2017-11-30 Johann Wolfgang Goethe-Universität Frankfurt am Main Treatment and diagnosis of non-proliferative diabetic retinopathy
US20210378995A1 (en) 2018-10-10 2021-12-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and topical pharmaceutical compositions for the treatment of skin microvascular dysfunction
CN113302298B (zh) 2018-11-09 2025-02-25 银杏生物制品公司 罗汉果甙的生物合成

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1056290A (en) * 1963-05-06 1967-01-25 Du Pont Dicycloalkyl ureas
CA2017383A1 (en) * 1989-06-08 1990-12-08 Raymond R. Martodam Use of vanilloids for the treatment of respiratory diseases or disorders
CA2036770C (en) * 1990-02-26 2003-09-09 Jeffrey P. Whitten Inhibitors of nitric oxide biosynthesis
US5445956A (en) * 1993-08-13 1995-08-29 The Regents Of The University Of California Recombinant soluble epoxide hydrolase
US5599984A (en) * 1994-01-21 1997-02-04 The Picower Institute For Medical Research Guanylhydrazones and their use to treat inflammatory conditions
JP2909620B2 (ja) * 1995-03-07 1999-06-23 参天製薬株式会社 Ｎ，ｎ−ジアルキルアミノフェニル基を有する新規アミノ酸誘導体
US6150415A (en) * 1996-08-13 2000-11-21 The Regents Of The University Of California Epoxide hydrolase complexes and methods therewith
US5955496A (en) * 1996-08-13 1999-09-21 The Regents Of The University Of California Dihydroxy-oxy-eicosadienoates

Also Published As

Publication number Publication date
EP1844767B1 (en) 2012-08-29
JP2002540767A (ja) 2002-12-03
DK1154764T3 (da) 2008-02-04
ES2291196T3 (es) 2008-03-01
US6150415A (en) 2000-11-21
DE60036690D1 (de) 2007-11-22
EP1154764B1 (en) 2007-10-10
CA2362331C (en) 2010-04-20
EP1154764A1 (en) 2001-11-21
WO2000048593A1 (en) 2000-08-24
ATE375153T1 (de) 2007-10-15
CA2362331A1 (en) 2000-08-24
DE60036690T2 (de) 2008-07-17
EP1154764A4 (en) 2005-02-16
EP1844767A3 (en) 2010-01-13
EP1844767A2 (en) 2007-10-17

Similar Documents

Publication Publication Date Title
AU3360800A (en) Epoxide hydrolase complexes and methods therewith
NZ505968A (en) Sulfonylamino derivatives which inhibit matrix- degrading metallproteinases
PT1178967E (pt) Derivados de quinolina como inibidores de enzimas mek
AU1282495A (en) Anthranilic acid derivative
ATE202702T1 (de) Verwendung von oestrogenagonisten und - antagonisten zur herstellung eines medikaments zur behandlung von atherosklerose, unabhängig von lipidsenkung
NZ514662A (en) Amine derivatives
AU3015289A (en) 2&#39;-deoxy-5-fluorouridine derivatives
GB1464583A (en) Preparation of quinazoline derivatives
PH19684A (en) Biologically acitve heterocyclic compounds
IL136359A (en) Dihydrobenzofuran substituted phthalazin-1-one derivatives and pharmaceutical compositions containing the same
DE69319764D1 (de) Verfahren zur Herstellung von Beta-Lactamderivaten und Zwischenprodukt für ihre Synthese
AU7767887A (en) Dihydropyridine derivatives
DE59408399D1 (de) Arylessigsäurederivate und ihre verwendung als fungizide
WO2003059907A1 (en) Nitrogenous heterocyclic compounds, process for preparation of the same and use thereof
AU1671288A (en) Dihydropyridines as paf antagonists
PL336857A1 (en) Heterocyclic compounds, method of obtaining them and pharmaceutic composition containing such compounds
DE69910568D1 (de) Furopyridinderivate und ihre therapeutische verwendung
YU47216B (sh) Proces za proizvodnju derivata 4,5,6,7-tetrahidrobenzimidazola
UA50722C2 (uk) Нітробензаміди, спосіб їх одержання (варіанти), фармацевтична композиція
BR9813923A (pt) N n - bis(sulfonil) hidrazinas úteis como agentes antineoplásicos
MY121785A (en) Hydroxamic acid derivatives as inhibitors of the production of soluble cd23
ATE278678T1 (de) Substituierte 1-aza-2-imino-heterocyclen und ihre verwendung als aktivatoren der nikotinergen acetylcholinrezeptoren
YU47797B (sr) Heterociklična jedinjenja koja sadrže azot i sumpor i postupci za njihovo dobijanje
AU553765B2 (en) Biologically active heterocyclic hydroximidates and thiolhydroximidates and carbamate ester derivatives thereof
DE68907141D1 (de) Rhizoxinderivate und ihre verwendung als antitumormittel.

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase